Objective  To explore the effect of coenzyme Ⅰ combined with lovastatin on cardiac function and the levels of serum inflammatory factors in patients with coronary heart disease (CHD). Methods  Retrospective analysis was performed on the clinical data of 120 CHD patients. Among them, 60 cases had been treated with lovastatin as the lovastatin group (lovastatin group), while another 60 cases were given lovastatin + coenzyme Ⅰ for injection as the combined medication group. The clinical efficacy and adverse reaction incidences between the two groups were compared, as well as the cardiac function (wall motion score index and LVEF), and serum inflammatory factors (high-sensitivity C-reactive protein, nuclear factor Kappa B), tumor necrosis factor-α and interleukin-1) and blood lipid (LDL-C, triglyceride, HDL-C and total cholesterol) levels before and after treatment. Results  The total clinical effective rate of the combined medication group was statistically higher than that of the lovastatin group (90.00% vs. 75.00%; χ²＝4.675, P＜0.05). The improvement of cardiac function, and serum inflammatory factors and blood lipid levels in the combined medication group was also better than that in the lovastatin group (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (16.67% vs. 6.67%; χ²＝2.911, P>0.05). Conclusion  In the treatment of CHD, the combination of coenzyme Ⅰ for injection and lovastatin significantly improves cardiac function and the regulation of blood lipid level. Its efficacy is better than that of lovastatin alone with high safety.